Sandra Horning
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers. Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Moderna faces stock dip amid cancer vaccine news and cash position. Recent articles note that Moderna holds a large cash reserve while advancing a deep cancer pipeline. A Phase 3 trial of its cancer vaccine reported positive results, which could broaden the company's product base. At the same time, the stock has fallen sharply, reflecting broader weakness in biotech and a pause in the recent rally. The decline occurs despite the cash strength and analyst price targets that remain well above current levels.
Transaction History
| RVMD | ▲ Buy | Grant | 1,191 | $0 | 6/18/2026 | View on chart |
| GILD | ▲ Buy | Grant | 1,146 | $0 | 4/30/2026 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 16,233 | — | 4/30/2026 | View on chart |
| RVMD | ▲ Buy | Grant | 3,142 | $0 | 6/26/2025 | View on chart |
| GILD | ▲ Buy | Grant | 1,516 | $0 | 5/7/2025 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 979 | — | 4/30/2025 | View on chart |
| RVMD | ▲ Buy | Grant | 4,800 | $0 | 6/20/2024 | View on chart |
| RVMD | ▲ Buy | Grant | 52,291 | — | 11/9/2023 | View on chart |
| RVMD | ▲ Buy | Grant | 27,696 | — | 11/9/2023 | View on chart |
| RVMD | ▲ Buy | Grant | 10,500 | $0 | 11/9/2023 | View on chart |
| GILD | ▲ Buy | Grant | 1,887 | $0 | 5/3/2023 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 670 | — | 4/28/2023 | View on chart |
| GILD | ▲ Buy | Option Exercise | 1,112 | — | 5/3/2022 | View on chart |
| MRNA | ▲ Buy | Option Exercise | 703 | $0 | 4/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
RVMD RASONQUE Receives Positive EU CHMP Opinion
The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.
RVMD RASONQUE Receives Positive EU CHMP Opinion. The European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorization for Revolution Medicines’ RASONQUE (daraxonrasib) in metastatic pancreatic cancer. This development supports the company’s pipeline and may broaden its commercial prospects in Europe. Analysts have maintained their target price, reflecting confidence in the drug’s potential.